How the Adoption of Health Technology Assessment Is Changing the Healthcare Landscape of India
Integration of Patient-Reported Outcomes (PROs) and the Patient Voice: A Review of 6 Health Technology Assessment (HTA) Agencies
A Tale of 2 Frameworks: Impact of ICER and NICE Updates on Future HTAs and Market Access
Changes in Medicare Part D Benefit Design Can Impact Availability of Future Treatments
Can We Afford Curative Therapies Without Sharing Risks? Perspectives on HTA and Affordability in This New Innovation Era
State-based Analysis: ICER-based Formularies Could Upend Access to Current Treatments in Medicaid
The Cost of Cures: What Does Zolgensma Teach Us About the Use of Cost-Effectiveness Assessments?
Biosimilars: Launch Insights From the Field
How are biosimilar manufacturers approaching patients, providers and payers? What can they do to differentiate? Xcenda shares insight from our field programs.
Tumor-Agnostic Therapy Assessment: Following Regulatory Approval, What Challenges Exist for HTAs?
Review of HTA Frameworks and Decisions for Next-Generation Sequencing in Precision Oncology
Rise of Complex Technologies and a Challenging Reimbursement Landscape: How a Forward-Looking Indirect Treatment Comparison Feasibility Study Can Help Navigate Market Access
How Digital Innovation Drives Improved Market Access Strategies
In this digital age, how can pharmaceutical manufacturers leverage innovative tools to prove their product's value proposition and overcome market access challenges?
Copay Accumulators: Are Your Patients Really at Risk?
Two experts in health economics and patient support team up to offer insight on how manufacturers can prepare for the impact of copay accumulators.
Can Patients Help Influence Drug Development? Where are We with Respect to Patient Input on Early Scientific Advice in North America and Europe?
Medicare Part B: Do Providers Choose Treatment Based on Payment?
What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.
Xcenda Collaborated with MAPRx to Publish New Report Addressing Medicare Part D Challenges to Beneficiaries
Medicare Physician-Administered Drugs: Do Providers Choose Treatment Based on Payment Amount?
Japan’s Ongoing Shift From a Traditional Reimbursement Assessment to a Novel Cost-Effectiveness Submission Requirement
Taiwan: 10 Years of the Center for Drug Evaluation (CDE) Health Technology Assessment Division
How Policy Impacts Patient Support
What role does the changing healthcare coverage landscape play in support program demand and design?
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
Applying Cost-Effectiveness Thresholds to the Real World: Implications on Access for Medicare Beneficiaries
Rethink: Payer Strategies for Commercializing Cell and Gene Therapies
Insights from managed care executives on the future of coverage and outcomes evaluation.
Xcenda Examines the Impact of the Tax Cuts and Jobs Act on the Life Science Sector
Xcenda Collaborates with Family Reach on Critical Issue - Cancer-Related Financial Toxicity
What Do Payers Think About Digital Health Technologies
How are payers thinking about apps, wearables and other digital health technologies?
Medical Nutritional Therapy: Achieving Reimbursement Across the Globe for Unique Non-drug Therapy Options
Biologic Treatments for Severe Asthma—a Paradigm Shift From Targeted to More Personalized Medicine